Get started
Author

Sachin Marulkar

Clinical Outcomes and Stent Thrombosis Following Off-Label Use of Drug-Eluting Stents
2007 · Htut K. Win, Angel E. Caldera, et al. · JAMA · 342
Beyond Restenosis
2004 · Donald E. Cutlip, Amit G. Chhabra, et al. · Circulation · 302
Saphenous Vein Graft Stenting and Major Adverse Cardiac Events
2008 · Alanna Coolong, Donald S. Baim, et al. · Circulation · 150
PDF
Transplanted CD34+ Cell Dose Is Associated with Long-Term Platelet Count Recovery following Autologous Peripheral Blood Stem Cell Transplant in Patients with Non-Hodgkin Lymphoma or Multiple Myeloma
2010 · Patrick J. Stiff, Ivana Micallef, et al. · Transplantation and Cellular Therapy · 127
PDF
Survival in infants treated with sebelipase Alfa for lysosomal acid lipase deficiency: an open-label, multicenter, dose-escalation study
2017 · Simon A. Jones, Sandra Rojas-Caro, et al. · Orphanet Journal of Rare Diseases · 91
PDF
Utility of the Safe-Cross–guided radiofrequency total occlusion crossing system in chronic coronary total occlusions (Results from the Guided Radio Frequency Energy Ablation of Total Occlusions Registry Study)
2004 · Donald S. Baim, Greg Braden, et al. · The American Journal of Cardiology · 80
Plerixafor (Mozobil) for stem cell mobilization in patients with multiple myeloma previously treated with lenalidomide
2010 · I N M Micallef, A D Ho, et al. · Bone Marrow Transplantation · 63
Long-term survival with sebelipase alfa enzyme replacement therapy in infants with rapidly progressive lysosomal acid lipase deficiency: final results from 2 open-label studies
2021 · Suresh Vijay, Anais Brassier, et al. · Orphanet Journal of Rare Diseases · 39
Safety and efficacy of upfront plerixafor + G‐CSF versus placebo + G‐CSF for mobilization of CD34+ hematopoietic progenitor cells in patients ≥60 and <60 years of age with non‐Hodgkin's lymphoma or multiple myeloma
2013 · Ivana N. Micallef, Patrick J. Stiff, et al. · American Journal of Hematology · 39
PDF
Sebelipase alfa in children and adults with lysosomal acid lipase deficiency: Final results of the ARISE study
2021 · Barbara K. Burton, François Feillet, et al. · Journal of Hepatology · 37
Sebelipase alfa for lysosomal acid lipase deficiency: 5‐year treatment experience from a phase 2 open‐label extension study
2020 · Vĕra Malinová, Manisha Balwani, et al. · Liver International · 24
Long‐Term Sebelipase Alfa Treatment in Children and Adults With Lysosomal Acid Lipase Deficiency
2022 · Barbara K. Burton, Alejandra Consuelo Sanchez, et al. · Journal of Pediatric Gastroenterology and Nutrition · 22
Sebelipase alfa improves atherogenic biomarkers in adults and children with lysosomal acid lipase deficiency
2018 · Don P. Wilson, Mark Friedman, et al. · Journal of clinical lipidology · 19
Progression of liver disease in children and adults with lysosomal acid lipase deficiency
2017 · Barbara K. Burton, Nancy Silliman, et al. · Current Medical Research and Opinion · 19
Correction to: Long-term survival with sebelipase alfa enzyme replacement therapy in infants with rapidly progressive lysosomal acid lipase deficiency: final results from 2 open-label studies
2021 · Suresh Vijay, Anais Brassier, et al. · Orphanet Journal of Rare Diseases · 13
PDF
Prognostic value of tumour-associated regulatory T-cells as a biomarker in non-small cell lung cancer: a systematic review and meta-analysis
2024 · Kapil Khambholja, Manish Gehani, et al. · Systematic Reviews · 5
PDF
Long-term benefit of sebelipase alfa over 76 weeks in children and adults with lysosomal acid lipase deficiency (LALD) “ARISE”
2017 · Barbara K. Burton, Sachin Marulkar, et al. · Molecular Genetics and Metabolism · 4
Eliglustat safety profile based on a pooled analysis of data from four trials in Gaucher disease type I
2014 · Leorah Ross, Judith Peterschmitt, et al. · Molecular Genetics and Metabolism · 4
Similar 1 Year Survival of Patients Receiving Plerixafor (Mozobil*®) Plus G-CSF Versus Placebo Plus G-CSF Mobilized Autologous Grafts: Results From Two Phase 3 Randomized Trials in Patients with NHL or MM Undergoing Autologous Transplantation After Front-Line or Rescue Mobilization.
2009 · Ivana N Micallef, Patrick Stiff, et al. · Blood · 3
Mobilization with Plerixafor (Mozobil ®)Plus G-CSF Results in Superior Day 1 Collection of CD34+ Cells Compared to Placebo Plus G-CSF: Results From Two Randomized Placebo-Controlled Trials in Patients with Multiple Myeloma or Non-Hodgkin's Lymphoma.
2009 · Brian J. Bolwell, Auayporn P. Nademanee, et al. · Blood · 3
Plerixafor Plus G-CSF Is An Effective Regimen to Mobilize Hematopoietic Stem Cells in NHL Patients with Circulating Peripheral Blood CD34+ Cells/μl < 10.
2009 · Richard T. Maziarz, Ivana N Micallef, et al. · Blood · 3
Plerixafor (Mozobi ®)Plus G-CSF Is More Effective Than Placebo Plus G-CSF in Mobilizing CD34+ Hematopoietic Stem Cells in Patients with Multiple Myeloma Who Have Low (<20 cells/μl) Peripheral Blood CD34+ Cell Count.
2009 · Auayporn P. Nademanee, Edward Stadtmauer, et al. · Blood · 2
Plerixafor (Mozobil ®)Plus G-CSF Is Effective in Mobilizing Hematopoietic Stem Cells in Patients with Concurrent Thrombocytopenia Undergoing Autologous Hematopoietic Stem Cell Transplantation.
2009 · Ivana N Micallef, Eric Jacobsen, et al. · Blood · 2
Data for: Prognostic value of tumor-associated regulatory T-cells as a biomarker in non-small cell lung cancer: a systematic review and meta-analysis
2022 · Khambholja, Kapil, Gehani, Manish, et al. · Harvard Dataverse · 1
PS-196-Efficacy and safety of sebelipase alfa over 144 weeks in a diverse population of children and adults with lysosomal acid lipase deficiency
2019 · Barbara Burton, Alejandra Consuelo Sanchez, et al. · Journal of Hepatology · 1
Works count: 42
Citation count: 1,399
H-index: 14
I10-index: 15
Year
Topic
Type